Tvardi Therapeutics, Inc.(TVRD)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Tvardi Therapeutics, Inc. (TVRD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TVRD at 11.2/100 on a 32-signal composite quality model, placing it at rank #2,903 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TVRD by reported 13-F value include Slate Path Capital, VANGUARD CAPITAL MANAGEMENT, AMERICAN FINANCIAL GROUP, based on the most recent SEC filings. TVRD trades on the Nasdaq exchange and files with the SEC under CIK 1346830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tvardi Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
11.2/100
AI Rank
#2,903
Net Income
$-6.8M
TVRD key financials by period
Tvardi Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2024
10-K
$7.1M
$-29.4M
—
FY 2023
10-K
$21.0M
$-118.5M
—
FY 2022
10-K
$41.9M
$-85.5M
—
FY 2021
10-K
$23.0M
$-88.4M
—
FY 2020
10-K
$135.1M
$8.4M
4.0%
FY 2019
10-K
$19.9M
$-106.4M
—
Institutions holding TVRD
Institutional investors reporting a position in Tvardi Therapeutics, Inc. on SEC Form 13F.
